Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» NRX-101
NRX-101
The Neuropsychiatric Pipeline: 10 Late-Stage Therapies to Watch
BioSpace
Mon, 08/14/23 - 11:23 am
depression
Biogen
SAGE Therapeutics
zuranolone
Intra-Cellular Therapies
lumateperone
Alto Neuroscience
ALTO-100
schizophrenia
Karuna Therapeutics
KarXT
Cerevel Therapeutics
emraclidine
Acadia Pharmaceuticals
pimavanserin
Axesome Therapeutics
AXS-05
Alzheimer's agitation
NRx
NRX-101
bipolar disorder
Biohaven
troriluzole
OCD
VistaGen
fasedienol
social anxiety
Alvogen snags NRx's bipolar depression drug in $330M deal ahead of late-phase data drop
Fierce Biotech
Wed, 06/7/23 - 09:37 pm
Alvogen
bipolar disorder
NRX-101
clinical trials
NeuroRx plans pivotal trial after seeing hints of efficacy in suicidal patients
Fierce Biotech
Thu, 12/13/18 - 10:25 am
NeuroRx
NRX-101
suicidal bipolar depression
clinical trials
FDA Grants Breakthrough Therapy Designation to First Oral Drug for Suicidal Bipolar Depression
CP Wire
Tue, 11/13/18 - 09:44 am
NRX-101
NeuroRx
FDA
bipolar disorder
breakthrough therapies
